Skip to main content
SpringerLink
Log in

The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Current pharmacological therapy for Alzheimer’s disease (AD) includes the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine, and galantamine and the N-methyl d-aspartate receptor antagonist memantine. Based on the results of randomized controlled trials and several meta-analyses, ChEIs appear to show modest but statistically significant improvements on several measures, including cognition and global functioning. Given their modest effects, there is a lack of consensus among clinicians regarding issues related to initiation, optimal duration, and discontinuation of ChEI therapy across the spectrum of AD. There is evidence from long-term observational controlled studies that early initiation and persistent exposure to AD therapy lead to delays in nursing home admission and significantly slower rates of cognitive and functional impairment. In the moderate to severe stages of AD, therapeutic trials of higher dose ChEIs and the addition of memantine are recommended for patients who are no longer responding to lower doses. While side effects are generally mild and gastrointestinal in nature, these events can lead to significant morbidity in more susceptible patients with advanced disease. Patients should thus be regularly monitored for any potential serious side effects of ChEI therapy, which also may include syncope and bradycardia. At the terminal stages of AD, such as when patients become hospice eligible, attempts to cautiously discontinue all medications not necessary for quality of life, including AD drugs, should be made.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alzheimer's Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2014;10(2):e47–92. doi:10.1016/j.jalz.2014.02.001.

  2. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–83.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137–47.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Qaseem A, Snow V, Cross JT, Forciea MA, Hopkins R, Shekelle P, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370–8.

    Article  PubMed  Google Scholar 

  5. National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. London: National Institute for Health and Clinical Excellence (NICE); 2011.

    Google Scholar 

  6. Lanctôt KL, Rajaram RD, Herrmann N. Therapy for Alzheimer’s disease: how effective are current treatments? Ther Adv Neurol Disord. 2009;2(3):163–80.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994;51(1):41–5.

    Article  CAS  PubMed  Google Scholar 

  8. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S51–6.

    Article  PubMed  Google Scholar 

  9. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379–97.

    Article  PubMed  Google Scholar 

  10. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA. 1994;271(13):992–8.

    Article  CAS  PubMed  Google Scholar 

  11. Blackard WG, Sood GK, Crowe DR, Fallon MB. Tacrine. A cause of fatal hepatotoxicity? J Clin Gastroenterol. 1998;26(1):57–9.

    Article  PubMed  Google Scholar 

  12. Aricept (donepezil) [package insert]. Woodcliff Lake: Eisai Inc., Revised May 2014. http://www.aricept.com/docs/pdf/aricept_PI.pdf. Accessed 21 Feb 2015.

  13. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD001190.

    PubMed  Google Scholar 

  14. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211–25.

    CAS  PubMed Central  PubMed  Google Scholar 

  15. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013;13:56.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, et al. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012;27(6):421–32.

    Article  PubMed  Google Scholar 

  18. Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer’s disease: drug profile and clinical guidelines. CNS Neurosci Ther. 2013;19(5):294–301.

    Article  CAS  PubMed  Google Scholar 

  19. Schwartz LM, Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ. 2012;344:e1086.

    Article  PubMed  Google Scholar 

  20. Administrative and correspondence documents. In: FDA Drug Approval Package. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000Admincorres.pdf. Accessed 21 Feb 2015.

  21. Medical review(s). In: FDA Drug Approval Package. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf. Accessed 21 Feb 2015.

  22. Summary review. In: FDA Drug Approval Package. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000SumR.pdf. Accessed 21 Feb 2015.

  23. Exelon (rivastigmine) [package insert]. East Hanover: Novartis Pharmaceutical Corporation, Revised Oct 2013. https://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf. Accessed 21 Feb 2015.

  24. Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2013;52(4):225–41.

    Article  CAS  PubMed  Google Scholar 

  25. Birks JS, Grimley EJ. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2015. doi:10.1002/14651858.CD001191.pub3.

    PubMed  Google Scholar 

  26. Exelon Patch (rivastigmine) [package insert]. East Hanover: Novartis Pharmaceutical Corporation, Revised July 2013. https://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf. Accessed 21 Feb 2015.

  27. Small G, Dubois B. A review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007;23(11):2705–13.

    Article  CAS  PubMed  Google Scholar 

  28. Boada M, Arranz FJ. Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer’s disease treated with rivastigmine. Dement Geriatr Cogn Disord. 2013;35(1–2):23–33.

    Article  CAS  PubMed  Google Scholar 

  29. Articus K, Baier M, Tracik F, Kühn F, Preuss UW, Kurz A. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer’s disease. Int J Clin Pract. 2011;65(7):790–6.

    Article  CAS  PubMed  Google Scholar 

  30. Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14–22.

    Article  CAS  PubMed  Google Scholar 

  31. Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer’s disease: a retrospective analysis. Dement Geriatr Cogn Disord. 2010;29(5):406–12.

    Article  CAS  PubMed  Google Scholar 

  32. Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Int J Geriatr Psychiatry. 2011;26(4):356–63.

    Article  PubMed  Google Scholar 

  33. Winblad B, Kawata AK, Beusterien KM, Thomas SK, Wimo A, Lane R, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry. 2007;22(5):485–91.

    Article  PubMed  Google Scholar 

  34. Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33(5):341–53.

    Article  CAS  PubMed  Google Scholar 

  35. Molinuevo JL, Frölich L, Grossberg GT, Galvin JE, Cummings JL, Krahnke T, et al. Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch. Alzheimers Res Ther. 2015;7(1):9.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A, 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementia. CNS Neurosci Ther. 2013;19(10):745–52.

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer’s disease. Curr Med Res Opin. 2010;26(10):2441–7.

    Article  CAS  PubMed  Google Scholar 

  38. Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Velting DM. A 24-week, open-label extension study to investigate the long-term safety, tolerability, and efficacy of 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2015;29(2):110–6.

  39. Razadyne (galantamine) [package insert]. Titusville: Janssen Pharmaceuticals, Inc., Revised July 2013. http://www.razadyneer.com/sites/default/files/shared/pi/razadyne_er.pdf. Accessed 21 Feb 2015.

  40. Lilienfeld S. Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002;8(2):159–76.

    Article  CAS  PubMed  Google Scholar 

  41. Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;1:CD001747.

    PubMed  Google Scholar 

  42. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease. Neuropsychiatr Dis Treat. 2014;10:391–401.

    CAS  PubMed Central  PubMed  Google Scholar 

  43. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593.

    PubMed  Google Scholar 

  44. Herrmann N, Chau SA, Kircanski I, Lanctôt KL. Current and emerging drug treatment options for Alzheimer’s disease: a systematic review. Drugs. 2011;71(15):2031–65.

    Article  CAS  PubMed  Google Scholar 

  45. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2004;75(5):677–85.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Atri A, Rountree SD, Lopez OL, Doody RS. Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer’s disease: comparison of efficacy and effectiveness studies. Neurodegener Dis. 2012;10(1–4):170–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement. 2013;9(3):338–45.

    Article  PubMed  Google Scholar 

  48. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1(2):7.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Wattmo C, Wallin Å, Londos E, Minthon L. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord. 2011;25(1):63–72.

    Article  CAS  PubMed  Google Scholar 

  50. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SL, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867–73.

    Article  PubMed  Google Scholar 

  51. Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med. 2009;6(9):e1000157.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Hernandez RK, Farwell W, Cantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. J Am Geriatr Soc. 2009;57(11):1997–2003.

    Article  PubMed  Google Scholar 

  53. Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011;59(6):1019–31.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging. 2010;27(6):435–49.

    Article  PubMed  Google Scholar 

  55. Parsons C, McCorry N, Murphy K, Byrne S, O’Sullivan D, O’Mahony D, et al. Assessment of factors that influence physician decision making regarding medication use in patients with dementia at the end of life. Int J Geriatr Psychiatry. 2014;29(3):281–90.

    Article  PubMed  Google Scholar 

  56. Tjia J, Briesacher BA, Peterson D, Liu Q, Andrade SE, Mitchell SL. Use of medications of questionable benefit in advanced dementia. JAMA Intern Med. 2014;174(11):1763–71.

    Article  PubMed  Google Scholar 

  57. Weschules DJ, Maxwell TL, Shega JW. Acetylcholinesterase inhibitor and N-methyl-d-aspartic acid receptor antagonist use among hospice enrollees with a primary diagnosis of dementia. J Palliat Med. 2008;11(5):738–45.

    Article  PubMed  Google Scholar 

  58. Parsons C, Briesacher BA, Givens JL, Chen Y, Tjia J. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc. 2011;59(7):1253–9.

    Article  PubMed  Google Scholar 

  59. Shega JW, Ellner L, Lau DT, Maxwell TL. Cholinesterase inhibitor and N-methyl-d-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors. J Palliat Med. 2009;12(9):779–83.

    Article  PubMed Central  PubMed  Google Scholar 

  60. Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother. 2009;7(2):74–83.

    Article  CAS  PubMed  Google Scholar 

  61. Namenda (memantine) [package insert]. St. Louis: Forest Pharmaceuticals, Inc., Revised Oct 2013. http://pi.actavis.com/data_stream.asp?product_group=1901&p=pi&language=E. Accessed 21 Feb 2015.

  62. Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 2010;11(10):1765–71.

    Article  CAS  PubMed  Google Scholar 

  63. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res. 2013;24(3):358–69.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20–7.

    Article  CAS  PubMed  Google Scholar 

  65. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Group MM-M-S. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83–9.

    Article  CAS  PubMed  Google Scholar 

  66. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903.

    Article  CAS  PubMed  Google Scholar 

  67. Choi SH, Park KW, Na DL, Han HJ, Kim EJ, Shim YS, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin. 2011;27(7):1375–83.

    Article  CAS  PubMed  Google Scholar 

  68. Grossberg GT, Manes F, Allegri RF, Gutiérrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs. 2013;27(6):469–78.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.

    Article  CAS  PubMed  Google Scholar 

  70. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311(1):33–44.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  71. Patel L, Grossberg GT. Combination therapy for Alzheimer’s disease. Drugs Aging. 2011;28(7):539–46.

    Article  CAS  PubMed  Google Scholar 

  72. Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement. 2013;9(3):326–31.

    Article  PubMed  Google Scholar 

  73. Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMJ Open. 2012;2:e000917. doi:10.1136/bmjopen-2012-000917.

    Article  PubMed Central  PubMed  Google Scholar 

  75. Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014;. doi:10.1093/ijnp/pyu115.

    PubMed  Google Scholar 

  76. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  77. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  78. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004;363(9427):2105–15.

    Article  CAS  PubMed  Google Scholar 

  79. Holmes C, Burns A, Passmore P, Forsyth D, Wilkinson D. AD2000: design and conclusions. Lancet. 2004;364(9441):1213–4 (author reply 6–7).

    Article  PubMed  Google Scholar 

  80. Schneider LS. AD2000: donepezil in Alzheimer’s disease. Lancet. 2004;363(9427):2100–1.

    Article  PubMed  Google Scholar 

  81. Silver G, Kay R, Phillips R. A critical analysis of the AD2000 study. In: Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease. NICE. 2006. https://www.nice.org.uk/guidance/ta111/documents/appendix-a-a-critical-analysis-of-the-ad2000-study2. Accessed 22 April 2015.

  82. Namenda XR (memantine) [package insert]. St. Louis: Forest Pharmaceuticals, Inc., Revised Sept 2014. http://pi.actavis.com/data_stream.asp?product_group=1902&p=pi&language=E. Accessed 21 Feb 2015.

  83. Namzaric (memantine/donepezil) [package insert]. St. Louis: Forest Pharmaceuticals, Inc., Revised Dec 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206439lbl.pdf. Accessed 21 Feb 2015.

  84. Singh I, Grossberg GT. Critical appraisal and role of memantine extended-release in the management of Alzheimer’s disease. Degener Neurol Neuromuscul Dis. 2011;1:9–13.

    Google Scholar 

  85. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 2003;9(3):275–308.

    Article  CAS  PubMed  Google Scholar 

  86. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheime’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.

    Article  PubMed Central  PubMed  Google Scholar 

  87. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19(8):707–14.

    Article  PubMed  Google Scholar 

  88. Sasaki S, Horie Y. The effects of an uninterrupted switch from donepezil to galantamine without dose titration on behavioral and psychological symptoms of dementia in Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2014;4(2):131–9.

    Article  PubMed Central  PubMed  Google Scholar 

  89. Spalletta G, Caltagirone C, Padovani A, Sorbi S, Attar M, Colombo D, et al. Cognitive and affective changes in mild to moderate Alzheimer’s disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study. PLoS One. 2014;9(2):e89216.

    Article  PubMed Central  PubMed  Google Scholar 

  90. Cagnin A, Cester A, Costa B, Ermani M, Gabelli C, Gambina G, et al. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer’s disease. Neurol Sci. 2015;36(3):457–63.

  91. Han HJ, Lee JJ, Park SA, Park HY, Kim JE, Shim YS, et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer’s disease. J Clin Neurol. 2011;7(3):137–42.

    Article  PubMed Central  PubMed  Google Scholar 

  92. Massoud F, Desmarais JE, Gauthier S. Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr. 2011;23(3):372–8.

    Article  PubMed  Google Scholar 

  93. Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging. 2006;10(5):417–29.

    CAS  PubMed  Google Scholar 

Download references

Conflicts of Interest and Funding

G. T. Grossberg serves as a consultant for Forest, Novartis, Otsuka, Lundbeck, and Takeda. For his department, G. T. Grossberg serves on monitoring boards for Merck, Newron, and NIH and receives research support from Accera, Noven, Forest, and Novartis. GT Grossberg has received payment for lectures by Forest and Novartis. E. Feen and W. J. Deardorff have no relevant conflicts of interest. No funding was received for the preparation of this article.

Author information

Authors and Affiliations

  1. Saint Louis University School of Medicine, 1438 South Grand, St. Louis, MO, 63104, USA

    William James Deardorff, Eliahu Feen & George T. Grossberg

Authors
  1. William James Deardorff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eliahu Feen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George T. Grossberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George T. Grossberg.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deardorff, W.J., Feen, E. & Grossberg, G.T. The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease. Drugs Aging 32, 537–547 (2015). https://doi.org/10.1007/s40266-015-0273-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-015-0273-x

Keywords

Search

Navigation